The observed association between elevated Lp(a) levels and statin use is primarily driven by confounding by indication, reflecting the patients' higher baseline risk profile rather than a direct biological effect of the medication.
A. M. Hernandez, F. Santiago, J. M. Andreu Cayuelas et al.· European Heart Journal· 0 citations
The proportion of LLT-naïve ACS patients eligible for upfront combination therapy due to Lp(a)-driven predicted monotherapy failure (Lp(a)-PMF) is identified, and the real-world benefit of this strategy in achieving the absolute therapeutic target (LDL-C <55 mg/dL) is evaluated.
F. B. Santiago, J. M. Andreu Cayuelas, A. M. Hernandez et al.· European Heart Journal· 0 citations
In ACS patients, the predictive value of lipid biomarkers for disease severity is fundamentally modified by prior LLT, and in patients on prior LLT, Lp(a) emerged as a strong independent predictor of severe ASCVD, whereas lower apoB levels were paradoxically associated with higher disease burden, likely reflecting more...
A. M. Hernandez, F. Santiago, J. M. Andreu Cayuelas et al.· European Heart Journal· 0 citations
The findings strongly support the 2025 ESC/EAS Guidelines update: in patients with LDL-PMF, adding ezetimibe to high-intensity statins at discharge significantly increases the likelihood of achieving the <55 mg/dL target compared to monotherapy.
A. M. Hernandez, J. M. Andreu Cayuelas, F. B. Santiago et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.